Topics

Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA and Pfizer

10:55 EST 12 Feb 2020 | Speciality Pharma Journal

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY. The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIO®) (avelumab). Development efforts will now focus …

Original Article: Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA and Pfizer

NEXT ARTICLE

More From BioPortfolio on "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA and Pfizer"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...